Associated disorders | | | | | | |
COPD | 93 (36–237) | 56 (15–171) | 0.004 | 5 (0–19) | 5 (0–12) | 0.148 |
CNS disorder | 79 (25–223) | 119 (47–273) | 0.003 | 6 (0–18) | 5 (0–13) | 0.456 |
Previous antibiotic treatment | 96 (33–278) | 74 (28–192) | 0.028 | 7 (0–20) | 3 (0–10) | <0.001 |
Anti-pneumococcal vaccination | 92 (30–240) | 76 (31–178) | 0.253 | 6 (0–18) | 3 (0–10) | 0.032 |
Prior inhaled corticosteroids | 93 (35–235) | 66 (18–194) | 0.023 | 5 (0–19) | 5 (0–13) | 0.184 |
Physical examination | | | | | | |
Confusion | 80 (28–210) | 157 (61–552) | <0.001 | 5 (0–16) | 7 (0–34) | 0.189 |
Respiratory rate ≥30 breaths·min−1 | 86 (33–225) | 98 (22–275) | 0.791 | 5 (0–15) | 8 (2–28) | 0.001 |
Systolic blood pressure <90 mmHg | 85 (29–225) | 215 (66–819) | 0.019 | 5 (0–17) | 12 (6–21) | 0.066 |
Arterial oxygen saturation <90% | 78 (30–187) | 105 (30–297) | 0.037 | 5 (0–15) | 7 (1–20) | 0.007 |
Analytical parameters | | | | | | |
Glycaemia ≥250 mg·dL−1 | 84 (29–227) | 105 (41–299) | 0.229 | 5 (0–16) | 11 (1–37) | 0.021 |
BUN ≥30 or creatinine ≥1.4 mg·dL−1 | 79 (29–205) | 112 (38–322) | 0.016 | 5 (0–17) | 7 (0–19) | 0.249 |
Serum sodium <130 mmol·L−1 | 83 (28–218) | 138 (58–332) | 0.003 | 5 (0–17) | 5 (0–18) | 0.533 |
Radiology | | | | | | |
Multilobar involvement | 79 (29–213) | 143 (47–364) | 0.001 | 5 (0–16) | 5 (0–19) | 0.535 |
Pleural effusion | 79 (29–221) | 127 (43–300) | 0.026 | 5 (0–16) | 6 (0–20) | 0.433 |
Bacteraemia | 81 (29–210) | 218 (84–616) | <0.001 | 5 (0–17) | 12 (1–36) | 0.049 |